Charalampos Thomas

Dr. Charalampos Thomas


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2021 in Medicines
Verified
Journal Article
Open access
PDF file
CTCharalampos Thomas
Charalampos Thomas
Charalampos KonstantinidisCharalampos Konstantinidis
Charalampos Konstantinidis
Erectile Dysfunction (ED) is the persistent inability to attain and maintain an erection sufficient to permit satisfactory sexual performance, causing tremendous effects on both patients and their partners. The pathophysiology of ED remains a labyrinth. The underlying mechanisms of ED may be vasculogenic, neurogenic, anatomical, hormonal, drug-induced and/or psychogenic. Neurogenic ED consists of a large cohort of ED, accounting for about 10% to 19% of all cases. Its diversity does not allow an in-depth clarification of all the underlying mechanisms nor a “one size fits all” therapeutical approach. In this review, we focus on neurogenic causes of ED, trying to elucidate the mechanisms that lie beneath it and how we manage these patients.

22 December 2008 in Cases Journal
Verified
Journal Article
Open access
PDF file
PKPanagiotis Kartsaklis
Panagiotis Kartsaklis
Charalampos KonstantinidisCharalampos Konstantinidis
Charalampos Konstantinidis
CTCharalampos Thomas
Charalampos Thomas
MTMaria Tsimara
Maria Tsimara
SASotirios Andreadakis
Sotirios Andreadakis
AGAristomenis Gekas
Aristomenis Gekas
Thrombosis or thromboflebitis of the superficial dorsal vein of the penis, known as penile Mondor's disease was first described by Braun-Falco in 1955.

24 April 2016
Verified
Journal Article
Closed access
CTCharalampos Thomas
Charalampos Thomas
CPConstantinos Psarros
Constantinos Psarros
AGAristomenis Gekas
Aristomenis Gekas
GVGerasimos P Vandoros
Gerasimos P Vandoros
Anastassios PhilippouAnastassios Philippou
Anastassios Philippou
MKMichael Koutsilieris
Michael Koutsilieris

16 December 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
Charalampos KonstantinidisCharalampos Konstantinidis
Charalampos Konstantinidis
EMEleni Moumtzi-Nakka
Eleni Moumtzi-Nakka
ANArchodia Nicolia
Archodia Nicolia
CTCharalampos Thomas
Charalampos Thomas
Introduction: traumatic brain injury (TBI) is very often associated with spasticity. Medical interventions may include medications such as baclofen, a Gamma-Aminobutyric Acid (GABA) -receptor agonist of poor lipid solubility. Intrathecal baclofen (ITB) administration is a contemporary treatment option which minimizes adverse effects in contrast with the oral form of the drug. Regarding low urinary tract dysfunction, TBI, as a suprapontine lesion, results in neurogenic detrusor overactivity. Frequency, urgency and urge incontinence are the predominant signs and symptoms of this condition. Our study aims to report the potential changes in bladder function in patients with spasticity, due to TBI, after the implantation of the baclofen pump and the control of spasticity. Material and Methods: We report three cases of TBI whose spasticity responded well to ITB. We evaluated our medical reports regarding bladder function retrospectively, before and after baclofen pump implantation. We compared the data of bladder diaries and urodynamic parameters. Results: Bladder function was improved in all patients. Regarding bladder diaries; the number of incontinence and micturition episodes was decreased and the volume per void was slightly increased. Regarding urodynamic parameters; bladder capacity and reflex volume increased, Pdetmax decreased, PVR was the same and DLPP was slightly decreased. Conclusions: Although the baclofen pump is implanted to treat spasticity, detrusor activity may be also affected. Therefore, patients’ urologic profiles should also be reevaluated after ITB. Further prospective studies are required to investigate the effect of ITB on bladder function in the clinical field and also at the basic science level.